Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Teva Pharmaceutical Industries
Sponsor:
Information provided by (Responsible Party):
Teva Pharmaceutical Industries
ClinicalTrials.gov Identifier:
NCT01630733
First received: June 26, 2012
Last updated: September 30, 2014
Last verified: September 2014
  Purpose

The primary objective of the study is to compare overall survival of patients randomized to receiving custirsen in combination with docetaxel (Arm A) with patients randomized to receive docetaxel alone (Arm B).


Condition Intervention Phase
Non-Small Cell Lung Cancer
Drug: Custirsen + Docetaxel
Drug: Docetaxel
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

Resource links provided by NLM:


Further study details as provided by Teva Pharmaceutical Industries:

Primary Outcome Measures:
  • Overall Survival [ Time Frame: 60 months ] [ Designated as safety issue: No ]
    Primary endpoint and variable for the study is overall survival (OS), defined as the time from date of randomization to the date of death from any cause.


Secondary Outcome Measures:
  • Progression Free Survival per RECIST v1.1 [ Time Frame: 60 months ] [ Designated as safety issue: No ]
    Progression Free Survival: time from date of randomization to first objective documented progression per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 or death due to any cause, whichever occurs first. Tumor lesions measured in at least one dimension with minimum size of 10 mm by CT scan, 10 mm caliper by clinical exam. Malignant lymph nodes must be >15 mm in short axis when assessed by CT scan. All measurable lesions up to a maximum of 2 lesions per organ and 5 in total representative of all involved organs should be identified as target lesions and measured and recorded.

  • Objective Response Rate as defined by RECIST v1.1. [ Time Frame: 60 months ] [ Designated as safety issue: No ]
    Objective Response (OR) is defined as achieving a best overall response of complete response (CR) or partial response (PR), as defined using RECIST v1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

  • Duration of Disease Control [ Time Frame: 60 months ] [ Designated as safety issue: No ]
    The Duration of Disease Control is defined as the time from randomization to the date of the first documented disease progression (taking as reference for progressive disease the smallest measurements recorded on study) or death, whichever occurs first.

  • Adverse events [ Time Frame: 60 months ] [ Designated as safety issue: Yes ]
    Adverse events and concomitant medications will be collected throughout the study up to 28 days after the last dose of study treatment. Medical history will be assessed, mutation status will be collected, if available, and an electrocardiogram will be performed at screening. Physical examination, vital signs, and laboratory evaluations will be conducted at screening and throughout the study.

  • Duration of Objective Response [ Time Frame: 60 months ] [ Designated as safety issue: No ]
    The evaluation of overall response at each assessment is a composite of target lesion response, non-target lesion response, presence of new lesions.

  • Disease Control Rate [ Time Frame: 60 months ] [ Designated as safety issue: No ]
    The disease control rate will be calculated as the total number of patients in each group with best overall response of CR, PR or Stable Disease (SD) divided by the total number of randomized patients in the group and will be compared similarly as Objective Response Rate (ORR.)


Estimated Enrollment: 1100
Study Start Date: September 2012
Estimated Study Completion Date: July 2017
Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Custirsen + Docetaxel

Arm A:

Custirsen: Three loading doses of custirsen 640mg IV over 2 hours administered in 5 to 9 days prior to Day 1 of Cycle 1, then custirsen 640 mg IV weekly every 21-day cycle Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle

Drug: Custirsen + Docetaxel
Custirsen: Three loading doses of custirsen 640mg IV over 2 hours administered in 5 to 9 days prior to Day 1 of Cycle 1, then custirsen 640 mg IV weekly every 21-day cycle; Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle
Active Comparator: Docetaxel:

Arm B:

Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle Continue treatment until disease progression, unacceptable toxicity, withdrawal of consent or protocol specified parameters to stop treatment.

Drug: Docetaxel
Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients must have a histologically or cytologically confirmed, unresectable, advanced or metastatic (Stage IV per AJCC 7th edition TNM staging) NSCLC
  2. Males or females ≥ 18 years of age at screening.
  3. Life expectancy of > 12 weeks from screening, according to the investigator's assessment.
  4. Patients must have received one prior line of platinum-based systemic anticancer therapy for advanced or metastatic NSCLC. Prior maintenance therapy is allowed and will be considered as the same line of therapy when continued at the end of a treatment regimen.
  5. Patients must have documented radiological disease progression either during or after the first-line therapy.
  6. Patients must have at least one measurable lesion per RECIST 1.1 criteria.
  7. ECOG performance status of 0 or 1 at screening.
  8. Have adequate values, bone marrow, renal and liver functions at screening as defined below:

    • Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
    • Platelet count ≥ 100 x 109/L
    • Hemoglobin ≥ 9 g/dL
    • Serum creatinine ≤ 1.5 x upper limit of normal (ULN)
    • Total Bilirubin ≤ 1.0 x ULN (unless elevated secondary to benign conditions such as Gilbert's disease)
    • AST and ALT ≤ 1.5 x ULN
  9. Resolution of any toxic effects of prior therapy to Grade ≤1 according to NCI CTCAE, version 4.0 (exception of alopecia and ≤ Grade 2 peripheral neuropathy).
  10. Females of child-bearing potential must have negative serum pregnancy test within 72 hours before randomization.
  11. Women of child-bearing potential will practice a highly effective method of birth control during and for 3 months after the chemotherapy/ custirsen last dose. Men of reproductive potential who are not surgically sterile must agree to abstain from sexual activity or use medically accepted and highly effective method of contraception during and for 6 months after the chemotherapy/custirsen last dose.
  12. Patients must be willing and able to give written informed consent prior to any protocol-specific procedures being performed and comply with the protocol requirements for the duration of the study.

Exclusion Criteria:

  1. Patients treated with any systemic anti-cancer therapy for NSCLC within 21 days prior to randomization (6 weeks for Bevacizumab).
  2. Radiotherapy ≤ 2 weeks prior to randomization. Patients must have recovered from all radiotherapy-related toxicities.
  3. Major surgical procedure within 4 weeks prior to randomization. Patient must have recovered from all surgery-related complications.
  4. Patients with known CNS metastases (Patients with any clinical signs of CNS metastases must have a CT or MRI of the brain to rule out CNS metastases in order to be eligible for participation in the study). Patients who have had brain metastases treated with radiotherapy or surgically removed with no residual disease confirmed by imaging; patients should be clinically stable and off corticosteroid treatment at least 3 weeks prior to randomization).
  5. Patients with current diagnosis or a history of another active primary malignancy (except in situ carcinoma of the cervix, adequately treated non-melanomatous skin cancers, clinically localized prostate cancer, superficial bladder cancer or other malignancy treated at least 5 years previously with no evidence of recurrence).
  6. Severe or unstable medical conditions such as heart failure, ischemic heart disease, uncontrolled hypertension, uncontrolled diabetes mellitus, psychiatric condition, as well as an ongoing cardiac arrhythmia requiring medication (≥ Grade 2, according to NCI CTCAE v4.0) or any other significant or unstable concurrent medical illness that in the opinion of the Investigator would preclude protocol therapy.
  7. A history of events such as myocardial infarction, cerebrovascular accident or acute hepatitis within 3 months of randomization or treatment of a major active infection within one month of randomization, or any other significant event that in the opinion of the Investigator would preclude protocol therapy.
  8. Planned concomitant participation in another clinical trial of an experimental agent, vaccine, or device. Concomitant participation in observational studies is acceptable.
  9. Female patients who are breastfeeding.
  10. Patients previously treated with docetaxel for NSCLC or with known severe hypersensitivity to taxane therapies.
  11. Patients with known and documented EGFR mutation who have not received an EGFR inhibitor.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01630733

Contacts
Contact: Teva US Medical Information 1-800-896-5855

  Hide Study Locations
Locations
United States, Arizona
Teva Investigational Site 10276 Not yet recruiting
Tucson, Arizona, United States
United States, California
Teva Investigational Site 10278 Completed
Sacramento, California, United States
United States, Florida
Teva Investigational Site 10269 Recruiting
Orlando, Florida, United States
Teva Investigational Site 10260 Recruiting
Soynton Beach, Florida, United States
United States, Georgia
Teva Investigational Site 10264 Active, not recruiting
Athens, Georgia, United States
United States, Illinois
Teva Investigational Site 10272 Recruiting
Joliet, Illinois, United States
United States, Kentucky
Teva Investigational Site 10261 Recruiting
Hazard, Kentucky, United States
United States, Missouri
Teva Investigational Site 10268 Recruiting
St. Louis, Missouri, United States
United States, North Carolina
Teva Investigational Site 10277 Recruiting
Winston Salem, North Carolina, United States
United States, Ohio
Teva Investigational Site 10270 Active, not recruiting
Akron, Ohio, United States
Teva Investigational Site 10262 Recruiting
Canton, Ohio, United States
Teva Investigational Site 10279 Active, not recruiting
Cleveland, Ohio, United States
United States, Tennessee
Teva Investigational Site 10263 Recruiting
Knoxville, Tennessee, United States
United States, Texas
Teva Investigational Site 10267 Active, not recruiting
Tyler, Texas, United States
Teva Investigational Site 10265 Recruiting
Tyler, Texas, United States
United States, Virginia
Teva Investigational Site 10274 Recruiting
Fairfax, Virginia, United States
Australia
Teva Investigational Site 78024 Not yet recruiting
Bedford Park, Australia
Teva Investigational Site 78018 Completed
East Bentleigh, Australia
Teva Investigational Site 78020 Recruiting
Heidelberg, Australia
Teva Investigational Site 78014 Recruiting
Hobart, Australia
Teva Investigational Site 78023 Recruiting
Kogarah, Australia
Teva Investigational Site 78022 Recruiting
Malvern, Australia
Teva Investigational Site 78019 Recruiting
Port Macquarie, Australia
Teva Investigational Site 78015 Recruiting
Toorak Gardens, Australia
Teva Investigational Site 78017 Recruiting
Westmead, Australia
Teva Investigational Site 78021 Recruiting
Wodonga, Australia
Teva Investigational Site 78016 Recruiting
Woodville, Australia
Germany
Teva Investigational Site 32231 Recruiting
Gauting, Germany
Teva Investigational Site 32230 Not yet recruiting
Grosshansdorf, Germany
Teva Investigational Site 32229 Recruiting
Halle (Saale), Germany
Teva Investigational Site 32225 Recruiting
Hamburg, Germany
Teva Investigational Site 32233 Recruiting
Kassel, Germany
Teva Investigational Site 32226 Not yet recruiting
Koeln, Germany
Teva Investigational Site 32228 Active, not recruiting
Mainz, Germany
Teva Investigational Site 32232 Not yet recruiting
Muenster, Germany
Hungary
Teva Investigational Site 51053 Recruiting
Budapest, Hungary
Teva Investigational Site 51052 Recruiting
Budapest, Hungary
Teva Investigational Site 51049 Recruiting
Budapest, Hungary
Teva Investigational Site 51050 Recruiting
Szolnok, Hungary
Israel
Teva Investigational Site 80030 Recruiting
Haifa, Israel
Teva Investigational Site 80029 Recruiting
Jerusalem, Israel
Teva Investigational Site 80027 Recruiting
Kfar Saba, Israel
Teva Investigational Site 80028 Recruiting
Tel Aviv, Israel
Teva Investigational Site 80026 Completed
Zerifin, Israel
Italy
Teva Investigational Site 30045 Recruiting
Ancona, Italy
Teva Investigational Site 30043 Recruiting
Bergamo, Italy
Teva Investigational Site 30048 Active, not recruiting
Cremona, Italy
Teva Investigational Site 30046 Recruiting
Genova, Italy
Teva Investigational Site 30044 Recruiting
Livorno, Italy
Teva Investigational Site 30050 Recruiting
Milano, Italy
Teva Investigational Site 30047 Active, not recruiting
Milano, Italy
Teva Investigational Site 30042 Active, not recruiting
Parma, Italy
Teva Investigational Site 30049 Active, not recruiting
Pavia, Italy
Korea, Republic of
Teva Investigational Site 87011 Recruiting
Busan, Korea, Republic of
Teva Investigational Site 87008 Recruiting
Daegu, Korea, Republic of
Teva Investigational Site 87006 Recruiting
Incheon, Korea, Republic of
Teva Investigational Site 87010 Recruiting
Jeonnam, Korea, Republic of
Teva Investigational Site 87009 Recruiting
Seongnam, Korea, Republic of
Teva Investigational Site 87007 Recruiting
Seoul, Korea, Republic of
Teva Investigational Site 87005 Recruiting
Seoul, Korea, Republic of
New Zealand
Teva Investigational Site 79002 Recruiting
Christchurch, New Zealand
Teva Investigational Site 79003 Not yet recruiting
Palmerston North, New Zealand
Teva Investigational Site 79001 Recruiting
Tauranga, New Zealand
Poland
Teva Investigational Site 53094 Recruiting
Olsztyn, Poland
Teva Investigational Site 53095 Recruiting
Poznan, Poland
Teva Investigational Site 53093 Not yet recruiting
Poznan, Poland
Teva Investigational Site 53096 Recruiting
Szczecin, Poland
Teva Investigational Site 53097 Not yet recruiting
Wroclaw, Poland
Russian Federation
Teva Investigational Site 50157 Recruiting
Arkhangelsk, Russian Federation
Teva Investigational Site 50153 Not yet recruiting
Moscow, Russian Federation
Teva Investigational Site 50152 Recruiting
Novosibirsk, Russian Federation
Teva Investigational Site 50156 Recruiting
Obninsk, Russian Federation
Teva Investigational Site 50158 Recruiting
Sochi, Russian Federation
Teva Investigational Site 50154 Recruiting
St. Petersburg, Russian Federation
Teva Investigational Site 50155 Recruiting
St. Petersburg, Russian Federation
Teva Investigational Site 50150 Not yet recruiting
St. Petersburg, Russian Federation
Teva Investigational Site 50151 Recruiting
Yaroslavl, Russian Federation
Singapore
Teva Investigational Site 91004 Not yet recruiting
Singapore, Singapore
Teva Investigational Site 91000 Recruiting
Singapore, Singapore
Teva Investigational Site 91003 Not yet recruiting
Singapore, Singapore
Teva Investigational Site 91002 Recruiting
Singapore, Singapore
Spain
Teva Investigational Site 31045 Recruiting
Alcorcon, Spain
Teva Investigational Site 31042 Recruiting
Barcelona, Spain
Teva Investigational Site 31050 Active, not recruiting
Castellon, Spain
Teva Investigational Site 31049 Not yet recruiting
Las Palmas de G.C., Spain
Teva Investigational Site 31044 Recruiting
Madrid, Spain
Teva Investigational Site 31047 Recruiting
Majadahonda-Madrid, Spain
Teva Investigational Site 31043 Recruiting
Sabadell, Spain
Teva Investigational Site 31046 Recruiting
Valencia, Spain
Teva Investigational Site 31048 Not yet recruiting
Valencia, Spain
Taiwan
Teva Investigational Site 83006 Recruiting
Changhua, Taiwan
Teva Investigational Site 83004 Recruiting
Taichung, Taiwan
Teva Investigational Site 83005 Recruiting
Taichung, Taiwan
Teva Investigational Site 83003 Recruiting
Tainan, Taiwan
Teva Investigational Site 83002 Recruiting
Taipei, Taiwan
Teva Investigational Site 83007 Not yet recruiting
Taipei, Taiwan
Thailand
Teva Investigational Site 92002 Not yet recruiting
Chanthaburi, Thailand
Teva Investigational Site 92005 Recruiting
Hat Yai, Songkhla, Thailand
Teva Investigational Site 92000 Recruiting
Nakhon Ratchasima, Thailand
Teva Investigational Site 92004 Not yet recruiting
Phayathai, Bangkok, Thailand
Teva Investigational Site 92003 Not yet recruiting
Phisanulok, Thailand
Teva Investigational Site 92001 Not yet recruiting
Saraburi, Thailand
Ukraine
Teva Investigational Site 58091 Recruiting
Dnipropetrovsk, Ukraine
Teva Investigational Site 58093 Not yet recruiting
Dnipropetrovsk, Ukraine
Teva Investigational Site 58096 Recruiting
Kharkiv, Ukraine
Teva Investigational Site 58090 Recruiting
Lutsk, Ukraine
Teva Investigational Site 58098 Not yet recruiting
Poltava, Ukraine
Teva Investigational Site 58095 Recruiting
Simferopol, Ukraine
Teva Investigational Site 58097 Recruiting
Sumy, Ukraine
Teva Investigational Site 58092 Recruiting
Uzhgorod, Ukraine
Teva Investigational Site 58094 Recruiting
Vinnytsya, Ukraine
Sponsors and Collaborators
Teva Pharmaceutical Industries
  More Information

No publications provided

Responsible Party: Teva Pharmaceutical Industries
ClinicalTrials.gov Identifier: NCT01630733     History of Changes
Other Study ID Numbers: TV1011-LC-303, 2012‐002447‐14
Study First Received: June 26, 2012
Last Updated: September 30, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Teva Pharmaceutical Industries:
Metastatic
Stage IV
Advanced
lung cancer

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Docetaxel
Antimitotic Agents
Antineoplastic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators

ClinicalTrials.gov processed this record on November 27, 2014